NIH 1991 · ASMBS 2022 · Medicare · 5 payer policies

Bariatric Surgery Eligibility Checker

Enter your height, weight, age, and comorbidities to see whether you qualify under the academic guidelines (NIH 1991, ASMBS 2022) and under the major US payer clinical policy bulletins (Medicare NCD 100.1, Aetna CPB 0157, Cigna 0051, UnitedHealthcare, BCBS FEP, Humana Medicare Advantage). Every payer entry links back to the source document and shows when it was last verified.

Payer data last verified October 2026. Re-verified quarterly per the staleness audit.

Obesity-related comorbidities (check all that apply)
BMI 39.5
Class 2 obesity
Eligibility under each standard
NIH 1991 Consensus (academic standard)
Academic guideline
Not eligible
  • · Psychological evaluation required at PA submission.
  • ✕ BMI 39.5 is below the BMI-alone threshold of 40.
  • ✕ BMI-with-comorbidity pathway requires a qualifying comorbidity (T2D, OSA, etc.) — none selected.
ASMBS / IFSO 2022 (current academic standard)
Academic guideline
Likely eligible
  • · BMI 39.5 meets the BMI-alone threshold of 35.
Medicare NCD 100.1
Payer policy
Not eligible
  • ✕ BMI-with-comorbidity pathway requires a qualifying comorbidity (T2D, OSA, etc.) — none selected.
Aetna CPB 0157
Payer policy
Not eligible
  • · Psychological evaluation required at PA submission.
  • ✕ BMI 39.5 is below the BMI-alone threshold of 40.
  • ✕ BMI-with-comorbidity pathway requires a qualifying comorbidity (T2D, OSA, etc.) — none selected.
Cigna Coverage Policy 0051
Payer policy
Likely eligible
  • · BMI 39.5 meets the BMI-alone threshold of 35.
  • · Psychological evaluation required at PA submission.
UnitedHealthcare
Payer policy
Not eligible
  • · Psychological evaluation required at PA submission.
  • ✕ BMI 39.5 is below the BMI-alone threshold of 40.
  • ✕ BMI-with-comorbidity pathway requires a qualifying comorbidity (T2D, OSA, etc.) — none selected.
Blue Cross Blue Shield (FEP reference)
Payer policy
Not eligible
  • ✕ BMI 39.5 is below the BMI-alone threshold of 40.
  • ✕ BMI-with-comorbidity pathway requires a qualifying comorbidity (T2D, OSA, etc.) — none selected.
Humana Medicare Advantage (HUM-1020-005)
Payer policy
Not eligible
  • ✕ BMI-with-comorbidity pathway requires a qualifying comorbidity (T2D, OSA, etc.) — none selected.

What this tool does and does not do

The tool reads the published BMI and comorbidity criteria from each payer's clinical policy bulletin and tells you whether you meet the medical-necessity threshold. It does not guarantee that any specific payer will approve your surgery. Final coverage decisions are made by the payer at the prior-authorization stage and depend on documentation that this tool cannot evaluate (psychological evaluation, supervised diet records, smoking cessation status, facility accreditation, surgeon network status, prior failed weight-loss attempts, etc.).

The academic standards

Two guidelines define the academic landscape:

  • NIH 1991 Consensus [1] — BMI ≥ 40, or BMI ≥ 35 with at least one serious comorbidity. The foundational standard cited by Medicare and most commercial insurers for three decades.
  • ASMBS / IFSO 2022 Indications [2] — lowered the threshold to BMI ≥ 35 regardless of comorbidities, and added a BMI 30-34.9 + metabolic disease pathway. The current academic standard; of the payers below, only Cigna has adopted it so far.

The payer landscape

Six US payers are included, each linked to its published clinical policy bulletin or coverage determination:

  • Medicare NCD 100.1 [3]: BMI ≥ 35 + at least one obesity-related comorbidity + prior unsuccessful medical treatment for obesity. There is no BMI-alone pathway, and facility certification has not been required since 2013. Covers RYGB, BPD/DS, and LAGB; sleeve gastrectomy is decided by the local Medicare contractor.
  • Aetna CPB 0157 [4]: BMI ≥ 40 alone or ≥ 35 with comorbidity (≥ 37.5 / ≥ 32.5 for Asian ancestry), an intensive behavioral weight-loss program of 12 or more sessions on separate dates (any duration) ending within 2 years of surgery, and a behavioral health assessment.
  • Cigna 0051 [5]: BMI ≥ 35 alone or 30–34.9 with an obesity-related comorbidity (the ASMBS 2022 thresholds), plus a multidisciplinary evaluation within 12 months covering failed medical weight loss, mental health clearance, and a nutrition evaluation.
  • UnitedHealthcare [6]: BMI ≥ 40 alone or 35–39.9 with comorbidity, a preoperative weight and diet history, and a psychosocial-behavioral evaluation (or a multidisciplinary preparatory program).
  • BCBS FEP 7.01.47 [7]: BMI ≥ 40 alone, or 35–39.9 with a weight-related condition, or 30–34.9 with type 2 diabetes, after failed conservative weight loss. State Blue plans set their own policies.
  • Humana Medicare Advantage [8]: Humana left employer commercial plans in 2025. Its Medicare Advantage policy follows NCD 100.1 and local Medicare rules: BMI ≥ 35 with a comorbidity, failed supervised weight loss, and a preparatory program with nutrition counseling. A psychological evaluation is needed only with a mental health history.

Why so many payers say BMI ≥ 40 vs ASMBS 2022 BMI ≥ 35

Payer policies update on slower cycles than academic guidelines. The ASMBS 2022 update [2] is the current academic recommendation, but Aetna, UnitedHealthcare, and BCBS FEP still use the older NIH 1991 threshold, and Medicare requires a comorbidity at any BMI. This means that a patient with BMI 36 and no comorbidities is academically eligible under ASMBS 2022 but not insurance-eligible under most payers. The tool surfaces this gap explicitly so patients understand which standard applies to which decision. If you are weighing surgery against a GLP-1 medication, or taking one around an operation, our GLP-1 and bariatric surgery cheat sheet covers where the two overlap.

Outcomes evidence underlying the eligibility criteria

The clinical guidelines are anchored on:

  • STAMPEDE [9]: Schauer 2017 NEJM 5-year RCT showed bariatric surgery + medical therapy produced −19% to −23% body weight loss vs −5% on intensive medical therapy alone, with substantially better T2D remission.
  • Adams 2007 [11]: Long-term mortality after gastric bypass cohort (n=15,850) reported a 40% reduction in all-cause mortality at 7 years post-surgery vs matched non-surgical controls.
  • Sjöström 2007 (SOS) [10]: The Swedish Obese Subjects study reported sustained mortality benefit (HR 0.71 at 10.9 years; HR 0.77 at 24 years).
  • Buchwald 2004 [12]: Meta-analysis of 22,094 patients across 136 studies reported mean excess weight loss of 61.2% and T2D resolution in 76.8%.

Important disclaimer

This tool is for educational purposes only and does not constitute medical advice or a payer coverage determination. Payer policies change quarterly and vary by plan, by employer group, and by state. Final eligibility for bariatric surgery requires evaluation by a qualified bariatric surgeon at an accredited center, prior authorization from your specific insurance plan, and the documentation specified by that plan. Anyone already taking a GLP-1 may be asked to pause it before anesthesia, and our pre-op stop-date calendar gives you a date to discuss with the surgical team. Patients with active eating disorders, untreated severe depression, or uncontrolled substance use should not pursue bariatric surgery without addressing those conditions first. Every payer criterion in this tool was independently verified against the cited source URL in October 2026.

References

  1. 1.NIH Consensus Development Panel. Gastrointestinal surgery for severe obesity. NIH Consensus Development Conference Statement. Am J Clin Nutr. 1992. PMID: 1733140.
  2. 2.Eisenberg D, Shikora SA, Aarts E, et al. 2022 American Society for Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO): Indications for Metabolic and Bariatric Surgery. Surg Obes Relat Dis. 2022. PMID: 36280539.
  3. 3.Centers for Medicare & Medicaid Services. National Coverage Determination (NCD) 100.1 — Bariatric Surgery for Treatment of Co-morbid Conditions Related to Morbid Obesity. CMS Medicare Coverage Database. 2013. https://www.cms.gov/medicare-coverage-database/view/ncd.aspx?NCDId=57
  4. 4.Aetna Inc. Aetna Clinical Policy Bulletin 0157 — Obesity Surgery. Aetna Medical Clinical Policy Bulletins. 2026. https://www.aetna.com/cpb/medical/data/100_199/0157.html
  5. 5.Cigna. Cigna Medical Coverage Policy 0051 — Bariatric Surgery. Cigna Medical Coverage Policies. 2026. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0051_coveragepositioncriteria_bariatric_surgery.pdf
  6. 6.UnitedHealthcare. UnitedHealthcare Commercial Medical Policy — Bariatric Surgery. UHC Provider Policies. 2026. https://www.uhcprovider.com/content/dam/provider/docs/public/policies/comm-medical-drug/bariatric-surgery.pdf
  7. 7.Blue Cross Blue Shield Federal Employee Program. FEP Medical Policy 7.01.47 — Bariatric Surgery. FEP Blue Cross Blue Shield. 2025. https://www.fepblue.org/-/media/PDFs/Medical-Policies/2024/June/June-2024-Medical-Policies/Remove--Replace/70147-Bariatric-Surgery.pdf
  8. 8.Humana Inc. Humana Medicare Advantage Medical Coverage Policy HUM-1020-005 — Bariatric Surgery. Humana Medical Coverage Policies. 2026. https://mcp.humana.com/tad/tad_new/Search.aspx?criteria=bariatric&searchtype=freetext&policyType=both
  9. 9.Schauer PR, Bhatt DL, Kirwan JP, Wolski K, Aminian A, Brethauer SA, Navaneethan SD, Singh RP, Pothier CE, Nissen SE, Kashyap SR; STAMPEDE Investigators. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes (STAMPEDE). N Engl J Med. 2017. PMID: 28199805.
  10. 10.Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, et al. Effects of Bariatric Surgery on Mortality in Swedish Obese Subjects. N Engl J Med. 2007. PMID: 17715408.
  11. 11.Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-Term Mortality after Gastric Bypass Surgery. N Engl J Med. 2007. PMID: 17715409.
  12. 12.Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004. PMID: 15479938.

Related research and tools

Data freshnessLast verified

Source: NIH and ASMBS criteria plus Medicare, Aetna, Cigna, UnitedHealthcare, BCBS FEP and Humana Medicare Advantage coverage policies.

Ready to start? Vetted GLP-1 providers

Vetted telehealth providers that prescribe GLP-1 online.

No insurance needed · vetted by our editors

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money

8.2

Gala

Compounded semaglutide or tirzepatide at one all-doses price on a yearly plan, with free shipping

Read full review →

From $129/mo (starting dose)

Get started →
8.3

Found

Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s

Read full review →

From $289/4 wks (billed per 4 weeks)

Get started →
8.1

Oak

Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up

Read full review →

From $200/mo (starting dose)

Get started →